2008, Number 3
<< Back
Med Cutan Iber Lat Am 2008; 36 (3)
Good response at etanercept in patients with psoriasis and morbid obesity
Guiote DMV, Hernández-Gil SJ, Aguilar GG, Dulanto CC, Naranjo SR
Language: Spanish
References: 10
Page: 158-159
PDF size: 153.34 Kb.
Text Extraction
No abstract
REFERENCES
Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005;6:121-36.
Gottlieb A. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatologic Therapy 2004;17:401-8.
Lebwohl MG. Use of Etanercept in Dermatology Setting. Am J Clin Dermatol 2005;6:49-59.
Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000;66:348-52.
Enbrel (package insert). Thousand Oaks (CA): Amgen, 2004.
Goffe MD. Etanercept —an update. Skin Therapy Letter Dec 2004— Jan 2005;Vol 9, Number 10.
Elewski BE, Boh E, Papp K et al. Efficacy and safety of etanercept in patients with psoriasis: results of a global phase III study. J Am Acad Dermatol 2004;50:159.
Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32.
Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
Full text